Bausch Health Companies Inc. (BHC) · Oct 28, 2026 · Earnings

Bausch Health earnings beat as guidance rises again on Salix growth

Beat — Adjusted EPS $1.77 vs ~$1.25 consensus; revenue $2.94B vs ~$2.72B consensus

Bausch Health earnings beat consensus and the company raised 2026 guidance again, powered by Salix and stronger cash generation.

Bausch Health is a highly leveraged pharmaceutical company trying to grow its Salix-led core while preparing to separate Bausch + Lomb and use cash generation to reduce debt. The filing materially advances that story: the quarter beat published expectations, operating momentum broadened across most segments, and management raised its full-year outlook again. The company’s planned eye-health separation remains an important structural backdrop, but this release is primarily an execution and cash-flow update.

MetricQ3 2026Q3 2025 / prior expectationRead
Revenue$2.941B$2.681B; ~$2.72B consensus+10% reported, +8% organic; beat
Adjusted diluted EPS$1.77$1.16; ~$1.25 consensusBeat
Adjusted EBITDA attributable to BHC$1.305B$986M+32%
Adjusted cash flow from operations$782M$508M+54%
FY 2026 revenue guidance$10.975B–$11.175B$10.790B–$11.040B prior guideRaised
FY 2026 adjusted EBITDA guidance$4.315B–$4.415B$4.050B–$4.175B prior guideRaised

This was a genuine earnings beat, not just a favorable comparison. Adjusted diluted EPS of $1.77 exceeded the published consensus of roughly $1.25, while revenue of $2.94 billion topped consensus near $2.72 billion. The company also reported GAAP diluted EPS of $1.15 versus $0.48 a year ago.

Salix is carrying the core business, with the strongest growth concentrated in Xifaxan. Salix revenue rose 16% reported and 14% organically, with Xifaxan contributing 16% growth. Bausch Health excluding Bausch + Lomb delivered 8% organic growth, while Bausch + Lomb added another 7% organic growth. That is a better-quality result than a headline consolidated increase alone because most of the growth came from existing operations rather than acquisitions. 〔0〕

The guidance raise confirms that the beat is changing the full-year business outlook. Compared with the July 29 guidance, the company lifted consolidated revenue, adjusted EBITDA, and adjusted cash-flow ranges; the midpoint increases were roughly $160 million for revenue, $252.5 million for adjusted EBITDA, and $200 million for adjusted cash flow. Bausch Health excluding Bausch + Lomb received the larger operating upgrade, while Bausch + Lomb’s outlook also moved higher. 〔1〕 The prior guidance had already been raised in July, so the direction was partly anticipated; the magnitude is the new information.

Cash generation is improving the balance-sheet story, but leverage remains central. Adjusted operating cash flow reached $782 million in the quarter, and management said cash generation supported more than $500 million of net debt reduction. Cash and equivalents rose to $2.485 billion from $1.309 billion at year-end, while total debt obligations were still $20.168 billion. The $50 million buyback is therefore best read as a targeted dilution offset for future management awards, not a broad return-of-capital program.

The main operating blemish is Solta, where reported growth masks contraction in the underlying business. Solta revenue rose 18% because of the China distributor acquisition, but organic revenue fell 4%. That weakness is meaningful because it shows the quarter was not uniformly strong, although it was outweighed by Salix, Bausch + Lomb, and the broader diversified portfolio.

Bottom line: This filing strengthens the turnaround narrative: Bausch Health beat expectations, raised the outlook again, and generated more cash for deleveraging. The result matters because the improvement is increasingly visible in the underlying businesses, even with Solta’s organic decline and the still-heavy debt load.

What to watch next

Q4 results, with 2027 Xifaxan pricing in focus

Original filing on SEC EDGAR

Bausch Health earnings beat as guidance rises again on Salix growth | BHC Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.